ALEXIS Biochemicals: Thiolutin

Advanced Search

You are here: Product Lines > Chemokines & Cytokines > Antibiotics for Angiogenesis Research

ALX-380-208

Revised 03-Apr-08

Asterric acid
SYNONYMS	Dimethylosoic acid TAN 1415A WF 12880A
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Angiogenesis Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-208-M001		1 mg	220.00 USD

Product Specification

FORMULA:	C₁₇H₁₆O₈
MW:	348.3
CAS NUMBER:	577-64-0
SOURCE/HOST:	Isolated from Aspergillus terreus MST-FP1370.
PURITY:	≥99% (HPLC)
APPEARANCE:	White to off-white solid.
SOLUBILITY:	Soluble in 100% ethanol, methanol, dimethyl formamide or DMSO.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light.

Product Description

Antibiotic. Inhibitor of vascular endothelial growth factor (VEGF).

Product Specific Literature References

Studies in the biochemistry of micro-organisms. 115. Metabolites of Penicillium frequentans Westling: isolation of sulochrin, asterric acid, (+)-bisdechlorogeodin and two new substituted anthraquinones, questin and questinol: A. Mahmoodian and C.E. Stickings; Biochem. J. 92, 369 (1964) Abstract; Full Text
Asterric acid, a new endothelin binding inhibitor: H. Ohashi, et al.; J. Antibiot. (Tokyo) 45, 1684 (1992) Abstract
Fungal metabolites, asterric acid derivatives inhibit vascular endothelial growth factor (VEGF)-induced tube formation of HUVECs: H.J. Lee, et al.; J. Antibiot. (Tokyo) 55, 552 (2002) Abstract

Further Categories Containing This Product:

VEGFs & VEGF-Rs Other Products • Tyrosine Kinase Inhibitors

ALX-380-102

Revised 03-Apr-08

Borrelidin
SYNONYMS	2-(7-Cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxooxacyclooctadeca-4,6-dien-2-yl)cyclopentanecarboxylic acid Treponemycin U 78548 C2989
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Cell Cycle Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-102-MC05		0.5 mg	160.00 USD
ALX-380-102-M001		1 mg	240.00 USD

Product Specification

FORMULA:	C₂₈H₄₃NO₆
MW:	489.7
CAS NUMBER:	7184-60-3
RTECS:	ED8750000
SOURCE/HOST:	Isolated from Streptomyces sp.
PURITY:	≥98% (HPLC)
APPEARANCE:	White to off-white powder.
SOLUBILITY:	Soluble in DMSO or methanol.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HAZARD:	IRRITANT.

Product Description

Antibiotic. Inhibitor of bacterial and eukaryal threonyl-tRNA synthetase (ThrRS). Inhibitor of cyclin-dependent kinase (CDK). Shows angiogenesis inhibiting and antiviral activity.

Product Specific Literature References

Isolation of a cDNA clone for human threonyl-tRNA synthetase: amplification of the structural gene in borrelidin-resistant cell lines: K.J. Kontis and S.M. Arfin; Mol. Cell. Biol. 9, 1832 (1989) Abstract
Genetic analysis of mutations causing borrelidin resistance by overproduction of threonyl-transfer ribonucleic acid synthetase: J. Frohler, et al.; J. Bacteriol. 143, 1135 (1980) Abstract; Full Text
Increased levels of threonyl-tRNA synthetase in a borrelidin-resistant Chinese hamster ovary cell line: J.S. Gantt, et al.; PNAS 78, 5367 (1981) Abstract; Full Text
Chinese hamster ovary cells resistant to borrelidin overproduce threonyl-tRNA synthetase: S.C. Gerken and S.M. Arfin; J. Biol. Chem. 259, 9202 (1984) Abstract; Full Text
Borrelidin inhibits a cyclin-dependent kinase (CDK), Cdc28/Cln2, of Saccharomyces cerevisiae: E. Tsuchiya, et al.; J. Antibiot. 54, 84 (2001) Abstract
Borrelidin induces the transcription of amino acid biosynthetic enzymes via a GCN4-dependent pathway: E.L. Eastwood and S.E. Schaus; Bioorg. Med. Chem. Lett. 13, 2235 (2003) Abstract
Isolation of vivomycin and borrelidin, two antibiotics with anti-viral activity, from a species of Streptomyces (C2989): M. Lumb, et al.; Nature 206, 263 (1965) Abstract
A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases: B. Ruan, et al.; J. Biol. Chem. 280, 571 (2005) Abstract; Full Text

Further Categories Containing This Product:

CDK & Cyclin Inhibitors • tRNA / Related Products • Antibiotics - Antiviral / Anti-HIV • Antibiotics for Angiogenesis Research

ALX-380-062

Revised 03-Apr-08

Cytochalasin E
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Cytoskeletal Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-062-M001		1 mg	40.00 USD
ALX-380-062-M005		5 mg	160.00 USD

Product Specification

FORMULA:	C₂₈H₃₃NO₇
MW:	495.6
CAS NUMBER:	36011-19-5
MERCK INDEX:	14: 2790
SOURCE/HOST:	Isolated from Aspergillus clavatus.
PURITY:	≥98% (HPLC)
APPEARANCE:	White to off-white powder.
SOLUBILITY:	Soluble in DMSO.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light.
HAZARD:	TOXIC.

Product Description

Antibiotic. Inhibits angiogenesis and tumor growth. Depolymerizes actin filaments.

Product Specific Literature References

Inhibition of actin polymerization in blood platelets by cytochalasins: J.E. Fox & D.R. Phillips; Nature 292, 650 (1981) Abstract
Cytochalasin-E-Resistant Mutants of Coprinus cinereus: Isolation and Genetic, Biochemical, and Cytological Analyses: M. Tsukamoto, et al.; Fungal Genet. Biol. 20, 52 (1996) Abstract
Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth: T. Udagawa, et al.; J. Pharmacol. Exp. Ther. 294, 421 (2000) Abstract
Depolymerization of actin filament by cytochalasin E induces interleukin-8 production and up-regulates CD54 in the HeLa epithelial cell line: N. Ikewaki, et al.; Microbiol. Immunol. 47, 775 (2003) Abstract

Further Categories Containing This Product:

Interleukins Other Products • Antibiotics for Angiogenesis Research • Microtubule Modulators • Antitumor Antibiotics • Actin / Related Products • Alkaloids

ALX-380-110

Revised 03-Apr-08

17-DMAG
SYNONYMS	17-[2-(Dimethylamino)ethyl]amino-17-desmethoxygeldanamycin NSC 707545
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Angiogenesis Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-110-C100		100 µg	50.00 USD
ALX-380-110-M001		1 mg	150.00 USD

Product Specification

FORMULA:	C₃₂H₄₈N₄O₈
MW:	616.8
CAS NUMBER:	150270-08-9
SOURCE/HOST:	Semisynthetic from geldanamycin (Prod. No. ALX-380-054).
PURITY:	≥99%
APPEARANCE:	Purple to black powder.
SOLUBILITY:	Soluble in water, 100% ethanol (10mg/ml) or DMSO (>25mg/ml).
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light.

Product Description

Less toxic, more potent synthetic derivative of geldanamycin. Inhibitor of angiogenesis. Inhibitor of heat shock protein 90 (HSP90). Inducer of apoptosis with higher antitumor activity than 17-AAG (Prod. No. ALX-380-091).

Product Specific Literature References

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats: M.J. Egorin, et al.; Cancer Chemother. Pharmacol. 49, 7 (2002) Abstract
Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats: S.M. Musser, et al.; Cancer Chemother. Pharmacol. 52, 139 (2003) Abstract
Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90: J.M. Jez, et al.; Chem. Biol. 10, 361 (2003) Abstract
Synthesis and biological activities of novel 17-aminogeldanamycin derivatives: Z.Q. Tian, et al.; Bioorg. Med. Chem. 12, 5317 (2004) Abstract
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator: G. Kaur, et al.; Clin. Cancer Res. 10, 4813 (2004) Abstract
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin: E.E. Bull, et al.; Clin. Cancer Res. 10, 8077 (2004) Abstract
ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition: H. Dote, et al.; Cancer Res. 65, 6967 (2005) Abstract
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative: M. Hollingshead, et al.; Cancer Chemother. Pharmacol. 56, 115 (2005) Abstract
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models: V. Smith, et al.; Cancer Chemother. Pharmacol. 56, 126 (2005) Abstract
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance: E.R. Glaze, et al.; Cancer Chemother. Pharmacol. 56, 637 (2005) Abstract
17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types: D.R. Gossett, et al.; Gynecol. Oncol. 96, 381 (2005) Abstract
Structure-based design of 7-carbamate analogs of geldanamycin: G. Rastelli, et al.; Biooorg. Med. Chem. Lett. 15, 5016 (2005) Abstract
Generation of a novel anti-geldanamycin antibody: E. Barzilay, et al.; BBRC 330, 561 (2005) Abstract
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry: K. Hwang, et al.; J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830, 35 (2006) Abstract

Related Products

ALX-380-054	Geldanamycin
ALX-380-091	17-AAG

Further Categories Containing This Product:

Antibiotics - Apoptosis Inducers & Inhibitors • Tyrosine Kinase Inhibitors • Antitumor Agents (Enzyme Inhibitors) • Antitumor Antibiotics • HSP90 / HtpG / Related Products

ALX-380-273

Revised 03-Apr-08

Doxycycline . hyclate
SYNONYMS	Doxycycline . hydrochloride . hemiethanolate . hemihydrate
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Angiogenesis Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-273-G001		1 g	20.00 USD
ALX-380-273-G005		5 g	60.00 USD

Product Specification

FORMULA:	C₂₂H₂₄N₂O₈ . HCl . 0.5C₂H₆O . 0.5H₂O
MW:	444.4 . 36.5 . 23.0 . 9.0
CAS NUMBER:	24390-14-5
MERCK INDEX:	14: 3440
RTECS:	QI8925000
SOURCE/HOST:	Semisynthetic from oxytetracycline.
PURITY:	≥98% (Assay on dry basis)
APPEARANCE:	Yellow crystalline solid.
SOLUBILITY:	Soluble in water (50mg/ml).
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Hygroscopic.
HAZARD:	HARMFUL. MAY BE TERATOGENIC. MAY BE CARCINOGENIC.

Product Description

Broad spectrum antibiotic and bacteriostatic. Shows antiprotozoal properties. Potent inhibitor of MMPs (matrix metalloproteinases) in vivo. Inhibits collagen synthesis.

Product Specific Literature References

Alpha-6-deoxyoxytetracycline. I. Some biological properties: A.R. English; Proc. Soc. Exp. Biol. Med. 122, 1107 (1966) Abstract
A compilation of LD50 values in newborn and adult animals: E.I. Goldenthal; Toxicol. Appl. Pharmacol. 18, 185 (1971) Abstract
An efficacy trial of doxycycline chemoprophylaxis against leptospirosis: E.T. Takafuji, et al.; N. Engl. J. Med. 310, 497 (1984) Abstract
Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential: K. Suomalainen, et al.; Antimicrob. Agents Chemother. 36, 227 (1992) Abstract
Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline: R. Hanemaaijer, et al.; J. Biol. Chem. 272, 31504 (1997) Abstract; Full Text
Doxycycline and tissue repair in rats: S. Lamparter, et al.; J. Lab. Clin. Med. 139, 295 (2002) Abstract
Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry: R.A. Garcia, et al.; Mol. Pharmacol. 67, 1128 (2005) Abstract; Full Text
Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices: C. Franco, et al.; Am. J. Pathol. 168, 1697 (2006) Abstract; Full Text
Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia: D. Burggraf, et al.; Neurobiol. Dis. 25, 506 (2007) Abstract

Further Categories Containing This Product:

MMP Inhibitors • Antitumor Agents (Enzyme Inhibitors) • Antitumor Antibiotics • Antitumor Agents (Anti-proliferative)

ALX-350-119

Revised 20-Feb-08

Fumagillin
SYNONYMS	Fumidil B Fumadil B TNP-470
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Angiogenesis Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-350-119-MC05		0.5 mg	65.00 USD
ALX-350-119-M001		1 mg	105.00 USD

Product Specification

FORMULA:	C₂₆H₃₄O₇
MW:	458.6
CAS NUMBER:	23110-15-8
MERCK INDEX:	14: 4286
SOURCE/HOST:	Isolated from Aspergillus fumigatus.
PURITY:	≥95%
APPEARANCE:	Light yellow solid
SOLUBILITY:	Soluble in chloroform or diluted aqueous bases. Slightly soluble in methanol and other alcoholic solvents. Insoluble in water.
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Unstable in aqueous solutions with pH >9.0 or pH <5.0.
HANDLING:	Packaged under inert gas. Protect from light.
HAZARD:	HARMFUL.

Product Description

Inhibitor of angiogenesis and endothelial cell proliferation. Specific inhibitor of methionine aminopeptidase type II (MetAP-II). Antineoplastic. Anti-infective.

Product Specific Literature References

Fumagillin (H-3), a new antibiotic with amebicidal properties: C.M. Mc, et al.; Science 113, 202 (1951) Abstract
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth: D. Ingber, et al.; Nature 348, 555 (1990) Abstract
The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase: W.T. Lowther, et al.; PNAS 95, 12153 (1998) Abstract; Full Text
Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2: E.C. Griffith, et al.; PNAS 95, 15183 (1998) Abstract
Fumagillin treatment of intestinal microsporidiosis: J.M. Molina, et al.; N. Engl. J. Med. 346, 1963 (2002) Abstract
Whirling disease of salmonid fish: life cycle, biology, and disease: M.A. Gilbert & W.O. Granath, Jr.; J. Parasitol. 89, 658 (2003) Abstract
Fumagillin treatment of hepatocellular carcinoma in rats: an in vivo study of antiangiogenesis: I.S. Sheen, et al.; World J. Gastroenterol. 11, 771 (2005) Abstract
Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors: B. Lefkove, et al.; Expert Rev. Anti Infect. Ther. 5, 573 (2007), Review Abstract
FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470): G.J. Chen, et al.; J. Cell Biochem. 101, 1492 (2007) Abstract

Further Categories Containing This Product:

Aminopeptidases / Related Products • Fibroblast Growth Factors [FGFs] & Receptors / Related Products • Natural Products - Other Anti-infective Agents • Antitumor Antibiotics • Antitumor Agents (Anti-proliferative)

ALX-350-029

Revised 07-Oct-08

Herbimycin A
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Protein Kinase Inhibitors

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-350-029-C100		100 µg	110.00 USD
ALX-350-029-M001		1 mg	560.00 USD

Product Specification

FORMULA:	C₃₀H₄₂N₂O₉
MW:	574.7
CAS NUMBER:	70563-58-5
RTECS:	LX8930000
SOURCE/HOST:	Isolated from Streptomyces sp.
PURITY:	≥97%
APPEARANCE:	Yellow powder.
SOLUBILITY:	Soluble in DMSO.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+4°C
HANDLING:	Protect from light.

Product Description

Antibiotic. Cell permeable tyrosine kinase inhibitor. Inhibitor of HSP90, NF-κB activation and angiogenesis. Increases the sensitivity of certain cancer cells to chemotherapeutic agents. Blocks mitotic activity. Neurotoxic.

Product Specific Literature References

Herbimycin, a new antibiotic produced by a strain of Streptomyces: S. Omura, et al.; J. Antibiot. (Tokyo) 32, 255 (1979) Abstract
A new activity of herbimycin A: inhibition of angiogenesis: T. Yamashita, et al.; J. Antibiot. (Tokyo) 42, 1015 (1989) Abstract
Stimulation by Bt2cAMP of epidermal mucous metaplasia in retinol- pretreated chick embryonic cultured skin, and its inhibition by herbimycin A, an inhibitor for protein-tyrosine kinase: A. Obinata, et al.; Exp. Cell. Res. 193, 36 (1991) Abstract
IgE-induced tyrosine phosphorylation of phospholipase C-gamma 1 in rat basophilic leukemia cells: D.J. Park, et al.; J. Biol. Chem. 266, 24237 (1991) Abstract; Full Text
Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages: S.L. Weinstein, et al.; PNAS 88, 4148 (1991) Abstract
Inhibition of interleukin 3 and granulocyte-macrophage colony- stimulating factor stimulated increase of active ras.GTP by herbimycin A, a specific inhibitor of tyrosine kinases: T. Satoh, et al.; J. Biol. Chem. 267, 2537 (1992) Abstract; Full Text
New insight into oncoprotein-targeted antitumor effect: herbimycin A as an antagonist of protein tyrosine kinase against Ph1-positive leukemia cells: M. Okabe and M. Uehara; Leuk. Lymphoma 12, 41 (1993) Abstract
Prevention of anti-CD3 monoclonal antibody-induced thymic apoptosis by protein tyrosine kinase inhibitors: K. Migita, et al.; J. Immunol. 153, 3457 (1994) Abstract
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation: L. Whitesell, et al.; PNAS 91, 8324 (1994) Abstract; Full Text
Inhibition of PDGF-induced phospholipase D but not phospholipase C activation by herbimycin A: B.Y. Kim; BBRC 212, 1061 (1995) Abstract
Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy: T.-P.D. Fan, et al.; TIPS 16, 57 (1995), (Review) Abstract
Herbimycin A enhances apoptotic effect of chemotherapeutic drugs on K562 cells: H. Ren, et al.; Chin. Med. J. (Engl.) 111, 678 (1998) Abstract
Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs: M.V. Blagosklonny; Leukemia 16, 455 (2002) Abstract; Full Text
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells’ sensitivity to cytotoxic drugs: D.T. Jones, et al.; Blood 103, 1855 (2004) Abstract; Full Text
Herbimycin A abrogates nuclear factor-kappaB activation by interacting preferentially with the IkappaB kinase beta subunit: S. Ogino, et al.; Mol. Pharmacol. 65, 1344 (2004) Abstract; Full Text
Herbimycin A suppresses mitotic activity and egg production of female Schistosoma mansoni: J. Knobloch, et al.; Int. J. Parasitol. 36, 1261 (2006) Abstract

Further Categories Containing This Product:

Tyrosine Kinase Inhibitors • Neurotoxins • Phospholipase D / Related Products • Antibiotics for Angiogenesis Research • HSP90 / HtpG / Related Products

ALX-350-245

Revised 07-Apr-08

Lactacystin (native)
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Proteasome / Ubiquitin Modulators

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-350-245-MC01		0.1 mg	60.00 USD
ALX-350-245-MC05		0.5 mg	250.00 USD
ALX-350-245-M001		1 mg	445.00 USD

Product Specification

FORMULA:	C₁₅H₂₄N₂O₇S
MW:	376.4
CAS NUMBER:	133343-34-7
SOURCE/HOST:	Isolated from Streptomyces sp.
PURITY:	≥97% (HPLC)
APPEARANCE:	White to off-white powder.
SOLUBILITY:	Soluble in acetonitrile (20mg/ml), 100% ethanol (1mg/ml), methanol, DMSO (20mg/ml), dimethyl formamide (20mg/ml) or water (5mg/ml).
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Organic stock solutions are stable for 3 months when stored at -20°C. Subject to hydrolysis in aqueous buffers. We do not recommend storing the aqueous solutions for more than one day.
HANDLING:	Protect from light.

Product Description